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Phosphatidylinositol 4,5-biphosphate (PIP2) is a membrane phospholipid that con-
trols the activity of several proteins regulating cytoskeleton reorganization, cytokine 
gene expression, T  cell survival, proliferation, and differentiation. Phosphatidylinositol 
4-phosphate 5-kinases (PIP5Ks) are the main enzymes involved in PIP2 biosynthesis 
by phosphorylating phosphatidylinositol 4-monophosphate (PI4P) at the D5 position of 
the inositol ring. In human T lymphocytes, we recently found that CD28 costimulatory 
molecule is pivotal for PIP2 turnover by recruiting and activating PIP5Kα. We also found 
that PIP5Kα is the main regulator of both CD28 costimulatory signals integrating those 
delivered by TCR as well as CD28 autonomous signals regulating the expression of 
pro-inflammatory genes. Given emerging studies linking alterations of PIP2 metabolism 
to immune-based diseases, PIP5Kα may represent a promising target to modulate 
immunity and inflammation. Herewith, we characterized a recently discovered inhibitor 
of PIP5Kα, ISA-2011B, for its inhibitory effects on T lymphocyte functions. We found that 
the inhibition of PIP5Kα lipid-kinase activity by ISA-2011B significantly impaired CD28 
costimulatory signals necessary for TCR-mediated Ca2+ influx, NF-AT transcriptional 
activity, and IL-2 gene expression as well as CD28 autonomous signals regulating the 
activation of NF-κB and the transcription of pro-inflammatory cytokine and chemokine 
genes. Moreover, our data on the inhibitory effects of ISA-2011B on CD28-mediated 
upregulation of inflammatory cytokines related to Th17 cell phenotype in type 1 diabetes 
patients suggest ISA-2011B as a promising anti-inflammatory drug.
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inTrODUcTiOn
Phosphatidylinositol 4,5-biphosphate kinases (PIP5Ks) are a family of lipid kinases that phos-
phorylate phosphatidylinositol 4-phosphate on the D5 position of the inositol ring, thus inducing 
the neo-synthesis of phosphatidylinositol 4,5-biphosphate (PIP2) (1). In humans, PIP5K family 
consists of three isoforms (α, β, and γ) and further splice variants. T  lymphocytes express all 
TaBle 1 | general characteristics of patients with type 1 diabetes (T1D) including the phenotype of peripheral blood T lymphocytes.
number of T1D patients age (years) Diabetes duration (years) % hba1c cD4/cD8 ratio % cD28+ cells
14 34.4 ± 14 13.9 ± 9.8 8 ± 1.4 1.9 ± 0.8 87 ± 7
Values indicate mean ± SD. HbA1c, glycated hemoglobin.
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PIP5K isoforms, each displaying a specific subcellular localiza-
tion that ensures the spatiotemporal organization of distinct 
PIP2 pools (2–5).
In T lymphocytes, PIP2 is a precursor for second messengers, 
inositol triphosphate (IP3), and diacylglycerol (DAG). DAG is 
mainly involved in the activation of the RAS/protein kinase 
C θ pathway (6, 7), whereas soluble IP3 mediates the release 
of Ca2+ from the intracellular stores, an event that induces 
the activation of the Ca2+/calmodulin-dependent calcineurin. 
Calcineurin is responsible for the dephosphorylation and acti-
vation of NF-AT transcription factors, which translocate into 
the nucleus and contribute to the transcriptional activation of 
pivotal genes, such as the IL-2 gene (8). This pivotal signaling 
pathway requires signals delivered by both TCR and CD28 
co-stimulatory molecule (9, 10).
Phosphatidylinositol 4,5-biphosphate serves also as a 
substrate of class 1 PI3K that, by phosphorylating PIP2 on the 
D3 position of the inositol ring, generates phosphatidylinositol 
3,4,5-triphosphate (PIP3) lipids (11). PIP3 lipids recruit and 
activate the phosphoinositide-dependent protein kinase 1 
(PDK1)/Akt pathway. PI3K-PDK1/Akt has been involved in 
CD28 signals regulating the activation of the transcription factor 
NF-κB (12–15). NF-κB signaling pathway selectively regulates 
the expression of several genes, including survival genes (16) 
and pro-inflammatory cytokine/chemokine (17, 18). Moreover, 
PI3K/PDK1/Akt also activates the mammalian target of rapa-
mycin complex 1 (mTORC1) that is an important regulator 
of glucose metabolism (19). In particular, by upregulating the 
glycolytic pathway, PI3K/PDK1/Akt/mTORC1 favors the dif-
ferentiation of specific inflammatory Th cell subsets, such as 
Th17 (20), which are involved in the pathogenesis of several 
autoimmune diseases (21).
Among all PIP5K isoforms, PIP5Kα is predominantly 
responsible for PIP2 synthesis in response to TCR and CD28 
co-engagement. In particular, we have recently demonstrated 
that CD28 recruits and activates PIP5Kα at the immunological 
synapse (IS), thus inducing the PIP2 levels necessary for sustain-
ing TCR-stimulated Ca2+ influx, NF-AT nuclear translocation, 
and IL-2 gene expression (3, 4). We also found that PIP5Kα is the 
main regulator of CD28 autonomous signals that induce NF-κB 
transcriptional activity and the transcription of pro-inflammatory 
genes (4), in a PI3K-dependent manner (17). Given the pivotal role 
of PIP5Kα in the regulation of PIP2 synthesis in T lymphocytes 
and emerging studies, which link alterations of PIP2 metabolism 
to immune-based diseases (22), PIP5Kα may represent a promis-
ing target to modulate immunity and inflammation.
A small molecule derivative of 1,2,3,4-tetrahydroisoquinoline 
ISA-2011B has been recently identified as a potential inhibitory 
drug of PIP5Kα. ISA-2011B was found to bind with high affinity 
to PIP5Kα and to inhibit its protein expression to suppress 
growth of prostate tumor in mouse models (23, 24). In this study, 
we further characterized the mechanisms of action of ISA-2011B 
and the effects of this agent on T  lymphocyte activation and 
pro-inflammatory functions. We found that ISA-2011B was 
efficient in inhibiting PIP5Kα lipid-kinase activity in T  lym-
phocytes, without affecting PIP5Kα protein expression. We also 
evidenced that PIP5Kα activity inhibition by ISA-2011B strongly 
impairs CD3/CD28-induced Ca2+ influx, NF-AT transcriptional 
activity, and IL-2 gene expression as well as CD28 autonomous 
signals regulating NF-κB transcriptional activation and pro-
inflammatory cytokine/chemokine gene expression. Finally, the 
results obtained by analyzing the effects of ISA-2011B on CD28-
mediated upregulation of inflammatory IL-8, IL-6, and IL-17A 
genes in T  lymphocytes from type 1 diabetes (T1D) patients 
suggest ISA-2011B as a promising anti-inflammatory drug.
MaTerials anD MeThODs
T1D Patients and controls
Fourteen patients (male/female ratio = 1) with a clinically defined 
T1D, in accordance with the guidelines of the Expert Committee 
on the Diagnosis and Classification of Diabetes Mellitus (25), were 
enrolled from the Diabetes Unit of S.M. Goretti Hospital, Polo 
Pontino (Sapienza University of Rome). The Ethical Committee 
of the S.M. Goretti Hospital has approved the Study and all 
individuals gave their informed consent in written form. Patients 
were between 18 and 63  years old, had disease duration from 
1 to 31  years, and glycated hemoglobin (HbA1c)% from 6.2 to 
12.4. None of the patients showed any evidence of micro or mac-
roangiopathy (Table 1). Fifteen healthy donors (HD) buffy coats 
from the blood bank of Sapienza University (Rome, Italy) with no 
previous history of autoimmune diseases were used as controls.
cells, abs, and reagents
Human primary T cells were enriched from PBMCs of HD or T1D 
patients and cultured in RPMI 1640 supplemented with 5% human 
serum (Euroclone, UK), l-glutamine, penicillin, and streptomycin. 
CH7C17 Jurkat T cell line expressing CD28WT has been previ-
ously described (26). Murine L cells transfected with human, HLA-
DRB1*0101 (5-3.1), and 5-3.1 co-transfected with B7.1/CD80 
(5-3.1/B7) have been previously described (10, 27). The following 
Abs were used: goat anti-PIP5Kα (N-20), goat anti-PIP5Kα (C17), 
and mouse anti-HA (Santa Cruz Biotechnology, CA, USA); mouse 
anti-CD28.2, mouse anti-CD3 (UCHT1), and goat anti-mouse 
(GAM) (BD Biosciences, Milan, Italy). PI4,5P2, PI4P, PMA, and 
A23871 were purchased from Sigma-Aldrich (Milan, Italy) and 
SEB were from Toxin Technology (Sarasota, FL, USA). ISA-2011B 
has been previously described (24). PIP5K small molecule inhibitor 
was from Cancer Research Technology (CRT, London, UK).
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Plasmids, cell Transfection, and 
luciferase assays
HA-tagged PIP5Kα was previously described (4). The NF-κB 
luciferase gene under the control of six thymidine kinase NF-κB 
sites was kindly provided by J. F. Peyron (Faculté de Médicine 
Pasteur, Nice, France). The NF-AT luciferase reporter construct 
containing the luciferase gene under the control of the human 
IL-2 promoter NF-AT-binding site was kindly provided by C. 
Baldari (University of Siena, Siena, Italy).
For luciferase assays, 107 Jurkat cells were electroporated 
(at 260 V, 960 μF) in 0.5 ml RPMI 1640 supplemented with 20% 
FCS with 2 µg NF-κB luciferase or 10 µg NF-AT luciferase together 
with 5  µg pEGFP, keeping the total amount of DNA constant 
(40 µg) with empty vector. Twenty-four hours after transfection, 
cells were stimulated with 5-3.1 or 5-3.1/B7 cells pre-pulsed or 
not with SEB (1 µg/ml) at 37°C for 6 h in the presence of DMSO, 
as a vehicle control, or the indicated concentration of ISA-2011B. 
Luciferase activity was measured according to the manufacturer’s 
instruction (Promega). Luciferase activity determined in tripli-
cates was expressed as arbitrary luciferase units after normaliza-
tion to GFP values.
PiP5Kα Kinase assays and 
immunoblotting
Primary T  cells (20 ×  106) were pre-incubated for 6  h with the 
indicated concentration of ISA-2011B or DMSO, stimulated 
for 5 min with anti-CD28 (5 µg/ml), or anti-CD3 (5 µg/ml) Abs 
crosslinked with 20 µg/ml of GAM. CH7C17 CD28WT Jurkat cells 
were transfected with HA-PIP5Kα WT and treated for 6 h with the 
indicated concentration of ISA-2011B or DMSO. Cells were lysed 
for 30 min on ice in 1% Non-idet P-40 lysis buffer in the presence of 
inhibitors of proteases and phosphatases. Extracts were precleared 
for 1  h with Protein-G Sepharose, endogenous or exogenous 
PIP5Kα were immunoprecipitated and incubated with PI4P as 
previously described (28). Briefly, PI4P was resuspended in assay 
buffer (30 mM HEPES pH 7.4, 100 mM KCl, 1 mM EGTA, 2 mM 
MgCl2, 0.05% NP-40) and sonicated. Immunoprecipitated PIP5Kα 
was incubated with 50  µl assay buffer containing PI4P, MgATP 
(50 µM), and 32γ-ATP (adenosine triphosphate) for 15 min at 30°C. 
The organic phase that contained PIP2 was separated by thin-
layer chromatography (TLC) on Silica gel 20 × 10 plates (Merck, 
Darmstadt, Germany). The radioactive lipids were visualized by 
autoradiography. The identity of PIP2 and PI4P was confirmed by 
comparison with standard phospholipids revealed by iodine vapor. 
The spot corresponding to PIP2 was quantified by densitometric 
analysis using the ImageJ program (National Institute of Health, 
USA). Primary T cells were stimulated as indicated at 37°C. At the 
end of incubation, cells were harvested and lysed for 30 min on ice 
in 1% Non-idet P-40 lysis buffer in the presence of inhibitors of 
proteases and phosphatases. Extracts were resolved by SDS-PAGE 
and blotted onto nitrocellulose membranes. Blots were incubated 
with the indicated primary antibodies, extensively washed, and after 
incubation with horseradish peroxidase (HRP)-labeled goat anti-
rabbit or HRP-labeled GAM (Amersham), or (HRP)-labeled don-
key anti-goat Abs (Santa Cruz Biotechnology) developed with the 
enhanced chemiluminescence’s detection system (GE Healthcare).
cytotoxicity assay
The cytotoxicity of ISA-2011B on primary T cells was evaluated 
by both propidium iodide (PI) and Annexin V conjugates stain-
ing by using a commercially available kit (Molecular Probes Inc., 
Invitrogen, UK). Primary T cells were plated at 2 × 106 cells/ml 
in 48-well plates and treated with different doses of ISA-2011B 
or DMSO for 6 or 24  h. Cytotoxicity was analyzed by a BD 
Biosciences FACScalibur (Mountain View, CA, USA) by quan-
tifying the percentage of PI or Annexin V-positive cells. Results 
were calculated from at least three independent experiments and 
statistically analyzed using Student’s t-test.
Measurement of intracellular calcium 
concentration
Primary T cells (1.5 × 106/ml) were treated for 6 h with DMSO 
or 10  µM ISA-2011B, loaded with 20  µM Fluo-3 AM (Sigma) 
for 30 min at 37°C in 300 µl of RPMI 1640. Loaded cells were 
then washed and activated with anti-CD3 plus anti-CD28 Abs 
crosslinked with GAM at 37°C and immediately analyzed by a 
cytofluorimeter (FACScalibur, BD Biosciences). Changes in cell 
fluorescence were monitored every 24 s for 10 min by measuring 
fluorescence emission at 530 nm. The concentration of intracel-
lular calcium [Ca2+]i was calculated according to Grynkiewicz 
et al. (29).
real-time Pcr
Primary T cells or Jurkat cells were stimulated for the indicated 
times with 2  µg/ml anti-CD28.2 or anti-CD3 Abs (UCHT1) 
crosslinked with 2  µg/ml GAM Abs. Total RNA was extracted 
using RNeasy MicroKit (Qiagen) and was reverse-transcribed 
into cDNA by using Moloney murine leukemia virus reverse 
transcriptase (Invitrogen). TaqMan Universal PCR Master Mix, 
IL-8, IL-6, IL-17A, IL-2, and GAPDH primer/probe sets were 
purchased from Applied Biosystems. The relative quantification 
was performed using the comparative CT method. The mean 
value of primary T cells from HD stimulated with control isotype 
matched Abs was used as calibrator.
statistical analysis
Parametrical statistical analysis (mean and SD) was performed to 
evaluate differences between continuous variables through Prism 
5.0 (GraphPad Software, San Diego, CA, USA) using standard 
unpaired t-test. For multiple group comparisons, significant 
differences were calculated using the non-parametric Mann–
Whitney U test, and linear regression analysis was performed 
using the Pearson chi-squared test. For all tests, P values < 0.05 
were considered significant.
resUlTs
isa-2011B inhibits PiP5Kα  
lipid-Kinase activity
ISA-2011B is a diketopiperazine fused C-1 indol-3-yl substi-
tuted 1,2,3,4-tetrahydroisoquinoline derivative that exhibits a 
high binding affinity to PIP5Kα and was described to inhibit 
FigUre 2 | isa-2011B inhibits exogenously expressed PiP5Kα 
lipid-kinase activity. (a) Jurkat cells were transfected and cultured for 24 h 
with 20 µg control empty vector (Vec) or 20 µg HA-PIP5Kα and then treated 
for further 6 h with DMSO or 25 µM ISA-2011B. PIP5Kα kinase assays 
performed on anti-HA IP (upper panel). HA-PIP5Kα content was analyzed by 
western blotting (lower panel). (B) Fold inductions were quantified by 
densitometric analysis and normalized to HA-PIP5Kα levels. Data are 
expressed as fold induction over the basal level of cells transfected with 
empty vector and treated with DMSO. Bars show the mean ± SD of two 
experiments. Asterisks (***) indicate P < 0.001 calculated by Student’s t-test, 
compared with cells transfected with HA-PIP5Kα and treated with DMSO.
FigUre 1 | isa-2011B inhibits phosphatidylinositol 4-phosphate 
5-kinase (PiP5K)α lipid-kinase activity in primary T cells. (a) Primary 
T cells from healthy donors (HD) were treated for 6 h with DMSO or the 
indicated concentrations of ISA-2011B and then unstimulated (ctr) or 
stimulated for 5 min with saturating concentration of anti-CD3 (5 µg/ml) plus 
anti-CD28 Abs crosslinked with goat anti-mouse (20 µg/ml). PIP5K kinase 
assays were performed on anti-PIP5Kα immunoprecipitations and the 
reaction products were subjected to thin-layer chromatography followed by 
autoradiography (upper panel). An equal amount of cell lysate was analyzed 
for PIP5Kα content by Western blotting (lower panel). (B) Fold inductions 
were quantified by densitometric analysis and normalized to PIP5Kα levels. 
Bars show the mean ± SD of two experiments. Asterisks (*) indicate P < 0.05 
calculated by Student’s t-test.
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PIP5Kα protein expression in prostate cancer (PC)-3 cells (24). 
Here we further characterized ISA-2011B functions, by analyz-
ing its effects on the lipid-kinase activity of PIP5Kα, in primary 
T lymphocytes. Primary T cells were pre-treated for 6 h with the 
indicated concentration of ISA-2011B or DMSO, as a vehicle 
control, and then stimulated for 5  min with isotype matched 
or anti-CD3 plus CD28 Abs. Our previous data evidenced that 
these stimulating conditions were efficient as anti-CD3 or anti-
CD28 alone in activating PIP5Kα (3). Endogenous PIP5Kα was 
immunoprecipitated and its lipid-kinase activity was evaluated 
(Figure 1A). As previously demonstrated (3), CD3 plus CD28 
stimulation by agonistic Abs strongly increased the lipid-kinase 
activity of PIP5Kα in primary T cells. Pre-treatment of T cells 
with either 10 or 25 µM of ISA-2011B strongly impaired CD3/
CD28-mediated induction of PIP5Kα activity (Figures 1A,B). 
Although to a lesser extent, similar inhibitory effects of ISA-
2011B were observed on constitutive activity of exogenously 
expressed PIP5Kα in Jurkat cells (Figures 2A,B). For instance, 
we have previously demonstrated that PIP5Kα exhibits high 
constitutive activity when over-expressed (4). The analysis of 
PIP5Kα content revealed that ISA-2011B did not affect PIP5Kα 
protein levels after 6  h of treatment at neither 10 nor 25  µM 
(Figure S1 in Supplementary Material). Consistently with the 
data on PC-3 cells (24), treatment of primary T cells with 25 µM 
ISA-2011B significantly inhibited PIP5Kα protein expres-
sion after overnight and 24  h (Figure S1A in Supplementary 
Material).
Collectively these data evidence that ISA-2011B acts as a lipid-
kinase inhibitor of PIP5Kα.
isa-2011B impairs cD28 costimulatory 
signals
We have demonstrated that the lipid-kinase activity of PIP5Kα 
is crucial for the regulation of both CD3/CD28 costimulatory 
FigUre 3 | isa-2011B impairs cD28 costimulatory functions in Jurkat T cells. (a) NF-AT luciferase activity of Jurkat cells treated for 6 h with DMSO or the 
indicated concentration of ISA-2011B and stimulated in the absence (med) or presence of 5-3.1/B7 (B7) cells pre-pulsed or not with 1 µg/ml SEB. The results are 
expressed as the mean of luciferase units ± SD after normalization to GFP values. The data are representative of three independent experiments. (B,D) Real-time 
PCR was used to measure IL-2 mRNA (B) and IL-8 mRNA levels (D) in Jurkat cells treated with DMSO or the indicated concentration of ISA-2011B and stimulated 
for 6 h with control IgG or anti-CD28 Abs (D) or anti-CD3 plus anti-CD28 Abs (B). Data are expressed as fold inductions (F.I.) over the basal level of cells stimulated 
with control IgG and treated with DMSO. Bars show the mean ± SD of three independent experiments. (c) NF-κB luciferase activity of Jurkat cells treated for 6 h 
with DMSO or the indicated concentration of ISA-2011B and stimulated in the absence (med) or presence of B7-negative (%-3.1) or B7-positive (5-3.1/B7) cells. 
The results are expressed as the mean of luciferase units ± SD after normalization to GFP values. The data are representative of three independent experiments. 
Asterisks (*) and (**) indicate P < 0.05 and P < 0.01, respectively, calculated by Student’s t-test.
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signals and CD28 unique signals, in both primary T cells and 
Jurkat cells (3, 4). Pre-treatment of Jurkat cells with ISA-2011B 
strongly impaired NF-AT transcriptional activity induced 
by TCR stimulation alone (Figure S2A in Supplementary 
Material) or TCR and CD28 co-engagement (Figure 3A). ISA-
2011B treatment strongly reduced IL-2 mRNA levels induced 
by TCR and CD28 co-engagement (Figure  3B; Figure S2B 
in Supplementary Material). CD3 stimulation alone induced 
only a slight increase (twofolds) of IL-2 gene expression that 
was not significantly inhibited by ISA-2011B (Figure S2B in 
Supplementary Material). By contrast, ISA-2011B treatment 
did not exert any significant effects on NF-AT transcriptional 
activity induced by PMA plus A23871, which bypass PIP2 
involvement (Figure S2C in Supplementary Material). CD28 
autonomous signals regulating both NF-κB transcriptional 
activation (Figure 3C) and RelA/NF-κB-dependent IL-8 gene 
transcription (17, 18) were also significantly inhibited in ISA-
2011B-treated Jurkat cells (Figure 3D).
Before testing the effects of ISA-2011B on primary T cell 
functions, we performed cell viability analyses to identify 
the dose of ISA-2011B with lower cytotoxic activity. The 
results obtained by analyzing both cytotoxic (PI incorpora-
tion) or apoptotic (Annexin V staining) activities of different 
ISA-2011B doses revealed a significant induction of both 
cell mortality (Figure S3A in Supplementary Material) and 
apoptosis (Figure S3B in Supplementary Material) at 25 µM. 
By contrast, at the dose of 10 µM, ISA-2011B failed to induce 
significant cell death in primary T cells from HD. Thus, 10 µM 
was chosen as the optimal dose for the next experiments on 
primary T cells.
To assess whether the inhibition of PIP5Kα lipid-kinase activ-
ity by ISA-2011B could affect early and late CD28 costimulatory 
signals, we analyzed both TCR/CD28-dependent Ca2+ signaling 
cascade and IL-2 gene expression in primary T  cells. We have, 
indeed, demonstrated that CD28-co-stimulation is essential to 
induce a stronger and prolonged Ca2+ influx compared with 
TCR individual ligation, optimal NF-AT nuclear translocation, 
and IL-2 gene expression by regulating PIP2 turnover through 
PIP5Kα activation (3). Pre-treatment of primary T lymphocytes 
with 10 µM ISA-2011B strongly impaired the increment of Ca2+ 
levels mediated by CD3/CD28 co-stimulation (Figure  4A), 
without affecting Ca2+ influx induced by A23871 ionophore 
(Figure  4B). The inhibition rate of Ca2+ levels by ISA-2011B 
(85%) where comparable to those exerted on PIP5Kα lipid-kinase 
activity (82%). Consistently with these data, ISA-2011B treatment 
strongly inhibited IL-2 transcription induced by TCR plus CD28 
stimuli (Figure 4C).
isa-2011B inhibits cD28 Pro-inflammatory 
Functions
Most of CD28 unique signaling converges to the activation of 
NF-κB (30, 31) and to the expression of several genes, including 
pro-inflammatory cytokines and chemokines (17).
We next tested whether the impairment of PIP5Kα activity 
by ISA-2011B might affect CD28 pro-inflammatory functions 
FigUre 4 | isa-2011B impairs Tcr- and cD28-induced increase of [ca2+]i and il-2 gene expression in primary T cells. (a,B) Primary T cells from HD 
were treated for 6 h with DMSO or ISA-2011B (10 µM) and after loading T cells with Fluo-3-AM, Ca2+ levels ([Ca2+]i) were measured by cytofluorimetric analysis after 
stimulation with crosslinked anti-CD3 plus anti-CD28 Abs (a) or A23871 (2 µg/ml) for 10 min. Data are representative of three independent experiments. (c) 
Real-time PCR was used to measure IL-2 mRNA levels in primary T cells from healthy donors (n = 5) treated with DMSO or ISA-2011B (10 µg/ml) and stimulated for 
6 h with crosslinked anti-CD3 plus anti-CD28 Abs. Values, normalized on GAPDH, are expressed as arbitrary units. Median values: DMSO = 0.55; DMSO CD3 plus 
CD28 = 16.59; ISA-2011B = 0.25: ISA-2011B CD3 plus CD28 = 5.68. Lines represent median values and P values are indicated where significant (Mann–Whitney).
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in primary T  cells. Consistently with our previous data (17), 
CD28 stimulation, in the absence of TCR engagement, signifi-
cantly increased the mRNA levels of IL-6, IL-8, and IL-17A in 
T  lymphocytes from HD (Figure  5). On the contrary, no sig-
nificant increase in IL-6 and IL-8 gene expression was induced 
by CD28 stimulation in ISA-2011B-treated T  lymphocytes 
compared with cells treated with DMSO, as vehicle control 
(Figures  5A,B). CD28-induced IL-17A cytokine expression 
was also strongly downregulated by 94% following ISA-2011B 
treatment (Figure 5C).
These data suggest ISA-2011B as a drug candidate to dampen 
CD28 pro-inflammatory functions in T lymphocytes.
isa-2011B impairs cD28-Dependent  
Pro-inflammatory cytokine expression  
in T1D T lymphocytes
We have recently observed that the upregulation of pro-
inflammatory cytokines and chemokines by CD28 was extremely 
relevant in inflammatory diseases, such as multiple sclerosis 
(MS), where we evidenced that CD28 stimulation induced a 
strong upregulation of pro-inflammatory cytokines in a class 
1A PI3K-dependent manner (17). We extended this analysis 
to T  lymphocytes from T1D. High levels of pro-inflammatory 
cytokines have been associated with diabetic vascular compli-
cations (32). Thus, we analyzed the extent of cytokine gene 
expression in primary T  cells isolated from the peripheral 
blood of T1D patients. CD28 stimulation strongly increased 
the expression of IL-8, IL-6, and IL-17A. However, in contrast 
to that observed for MS patients (17), no significant differences 
in the entity of CD28 upregulation of cytokine gene expres-
sion were observed in T1D compared with HD (Figure S4 
in Supplementary Material). Pre-treatment of cells with ISA-
2011B significantly impaired CD28-induced upregulation of all 
cytokines (Figures 6A–C).
These data identify PIP5Kα as a potential therapeutic target to 
dampen CD28 pro-inflammatory signals in T1D T cells.
DiscUssiOn
PIP2 is a pivotal regulator of TCR signaling, by serving as a 
precursor of important second messengers and by directly 
binding several signaling proteins regulating T  cell activa-
tion (5, 33). During the early phases of TCR engagement by 
peptide–MHC complexes presented on the surface of APC, 
PIP2 concentrates at the IS (34) where it is rapidly metabolized 
by PLCγ1 for inducing sustained Ca2+ mobilization, IL-2 gene 
FigUre 5 | isa-2011B impairs cD28 autonomous signals inducing the 
expression of pro-inflammatory cytokine/chemokine. Primary T cells 
from healthy donors subjects (n = 12) were treated with DMSO or ISA-2011B 
(10 µM) and stimulated for 6 h (a,B) or 24 h (c) with control isotype-matched 
mAb or crosslinked anti-CD28.2 Abs. IL-6 (a), IL-8 (B), and IL-17A  
(c) mRNA levels were measured by real-time PCR and values, normalized on 
GAPDH, expressed as arbitrary units. Median values: IL-6, DMSO = 0.89, 
DMSO CD28 = 37.66, ISA-2011B = 1.33, ISA-2011B CD28 = 11.66; IL-8, 
DMSO = 0.9, DMSO CD28 = 10.19, ISA-2011B = 1.9, ISA-2011B 
CD28 = 2.0; IL-17A, DMSO = 0.76, DMSO + CD28 = 120.4, ISA-
2011B = 0.69, ISA-2011B CD28 = 7.0. Lines represent median values and P 
values are indicated where significant (Mann–Whitney). NS = not significant.
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expression, and optimal T cell proliferation (35). CD28 ampli-
fies and sustains TCR-dependent PLCγ1-mediated hydrolysis 
of PIP2 (36), thus leading to the generation of IP3 second mes-
senger and the consequent release of Ca2+ from the intracellular 
stores and from the CRAC channels in the plasma membrane 
FigUre 6 | PiP5Kα inhibition by isa-2011B impairs cD28-mediated 
upregulation of pro-inflammatory cytokines in primary T cells from 
type 1 diabetes (T1D) patients. (a) Primary T cells from T1D patients 
subjects were treated with DMSO or ISA-2011B (10 µg/ml) and stimulated for 
6 h (a,B) or 24 h (c) with control isotype-matched mAb or crosslinked 
anti-CD28.2 Abs (T1D CD28). IL-6 (A), IL-8 (B), and IL-17A (c) mRNA levels 
were measured by real-time PCR and values, normalized on GAPDH, 
expressed as arbitrary units. Median values: IL-6 (n = 10), DMSO = 0.77, 
DMSO CD28 = 18.99, ISA-2011B = 0.26, ISA-2011B CD28 = 8.27; IL-8 
(n = 10), DMSO = 4, DMSO CD28 = 37.74, ISA-2011B = 4.75, ISA-2011B 
CD28 = 20.3; IL-17A (n = 6), DMSO = 1.18, DMSO CD28 = 72.42, 
ISA-2011B = 0.27, ISA-2011B CD28 = 10.32. Lines represent mean values 
and P values are indicated where significant (Mann–Whitney).
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(37, 38). PIP5Kα isoform has been shown recruited to the 
plasma membrane in response to several receptors, where it 
synthesizes the PIP2 levels necessary for PLCγ activity, IP3 
generation, and optimal Ca2+ influx (39–41). More recently, we 
evidenced that CD28 recruits and activates PIP5Kα at the inter-
face between T  cells and APC, thus strongly contributing to 
PIP2 synthesis (3, 4). Therefore, inhibiting the biosynthesis of 
PIP2 by targeting PIP5Kα may be useful to treat immune-based 
diseases, such as autoimmunity. Herewith, we demonstrate 
that PIP5Kα inhibitor, ISA-2011B, is effective in inhibiting the 
CD28 costimulatory signals essential for optimal TCR-induced 
Ca2+ influx, NF-AT transcriptional activation, and IL-2 gene 
expression.
A critical contribution of PIP2 to T  cell biological func-
tions is to serve as a substrate to class 1 PI3K. Class 1A PI3K 
phosphorylates PIP2 and generates PIP3 (42), which by binding 
the PH domains of several signaling molecules, such as phos-
phoinositide-dependent protein kinase 1 (PDK1), AKT, and 
Vav1 (43), strongly contributes to the activation of the NF-κB 
pathway (12–15). The transcription factors of Rel/NF-κB family 
are critical regulators of the immune system by inducing the 
expression of over 150 inflammatory cytokines and chemokines 
(44). CD28 is known to be the main activator of PI3K. Indeed, 
CD28 short cytoplasmic tail contains an N-terminal YMNM 
motif that following phosphorylation binds to the p85 subunit 
of class 1A PI3K (45–47), in a TCR-independent manner (48). 
Furthermore, CD28 also ensures the replenishment of PIP2 
pools essential for optimal PI3K activity by recruiting and 
activating PIP5Kα through its C-terminal proline rich motif 
(3, 4). This autonomous capability of CD28 results to the selec-
tive activation of a non-canonical NF-κB2-like cascade leading 
to the expression of several genes, including survival genes of 
the Bcl-2 family (16), the LTR of HIV-1 virus (12), and pro-
inflammatory cytokine/chemokine (17, 18). Our data on the 
inhibitory effects mediated by ISA-2011B on CD28-delivered 
signals regulating both NF-κB activation and pro-inflammatory 
cytokine/chemokine gene expression strongly support a role of 
PIP5Kα in regulating PI3K-dependent inflammatory functions 
of T lymphocytes.
The pro-inflammatory functions of CD28 may be particularly 
important in the context of inflammatory diseases. For instance, 
we have recently evidenced that CD28-mediated upregula-
tion of pro-inflammatory cytokines (i.e., IL-8, IL-6, IL-21, and 
IL-17A) was higher in human primary T  lymphocytes from 
relapsing-remitting multiple sclerosis patients (RRMS) com-
pared with HD (17). We extended these data by demonstrating 
that CD28 autonomous signaling is active in upregulating 
pro-inflammatory cytokine/chemokine expression and Th17 
amplification also in T1D. T1D is an autoimmune disease caused 
by the selective disruption of pancreatic islet cells by autoreactive 
T lymphocytes and to lifelong dependence on exogenous insulin 
therapy. The pathogenetic basis of T1D involves both genetic and 
environmental factors (49, 50). High plasma concentrations of 
pro-inflammatory cytokines have been detected in patients with 
T1D and are thought to be responsible for long-term micro and 
macrovascular diabetic complications (51, 52). Although chronic 
hyperglycemia has been considered the major determinant of 
onset and progression of endothelial alterations (32, 53), patients 
under insulin intensive therapy continue to suffer from vascular 
complications (54). Thus, identifying factors and/or molecules, 
which may contribute to sustain inflammation in T1D, may 
effectively be useful for treating or even preventing disease 
progression.
Herewith, we provide evidence that CD28 stimulation in 
the absence of TCR engagement may contribute in elevating 
the levels of pro-inflammatory cytokines in T1D patients. In 
particular, we found that CD28 stimulation strongly upregulated 
IL-6 and IL-17A cytokine gene expression in T  lymphocytes 
from T1D. High levels of IL-6 (55, 56) and IL-17 (57–59) have 
been reported in T1D patients, thus underlying the emerg-
ing role of Th17  cell subset in the pathogenesis of T1D (60). 
Honkanen et  al. showed that peripheral blood CD4+ T  cells 
from new-onset T1D children produce higher levels of IL-17 
(58). Similarly, Marwaha and colleagues found an increased 
number of CD4+ T cells that produce IL-17 in new-onset T1D 
children (59). The increased levels of IL-17 in T1D have been 
attributed to the presence of pro-inflammatory cytokines that 
drive toward Th17 differentiation (55). In particular, Th17 cell 
differentiation in humans is orchestrated by IL-6 (61). Recent 
data from Hundhausen et al. evidenced that IL-6 responsiveness 
is enhanced in T lymphocytes from T1D (62). Consistently, we 
found that CD28 stimulation strongly upregulated IL-6 and 
IL-17A expression in T  cells from T1D patients. As observed 
in MS patients (17), CD28-mediated IL-17A gene expres-
sion was delayed (24 h) when compared with IL-6 (6 h), thus 
suggesting that CD28-induced production of IL-6 in turn 
cooperates with CD28 signaling in mediating IL-17A gene 
expression. These data are consistent with those of Santarlasci 
et  al., who demonstrated that CD28 stimulation alone could 
trigger Th17 T cells to produce IL-17A in an NF-κB-dependent 
manner (63).
By using specific pharmacological inhibitors, we evidenced 
that CD28-induced upregulation of pro-inflammatory cytokines 
in MS patients was dependent on CD28-associated class 1A 
PI3K activation (17). Highly selective small molecule inhibitors 
of class 1A inhibitors are currently in pre-clinical and clinical 
trials for the treatment of several inflammatory and autoimmune 
diseases (64). Since PIP2 is an essential limiting factor ensuring 
that the activation of PI3K and PIP5Kα is the main regulator 
of CD28-mediated refilling of PIP2 pools (3, 33), PIP5Kα may 
represent a valid therapeutic candidate for treating inflamma-
tory diseases. Our data on the strong inhibitory effect exerted by 
treating primary T cells with ISA-2011B suggest that targeting 
the CD28/PIP5Kα signaling pathway may, therefore, provide 
an attractive therapeutic approach for the resolution of injuri-
ous inflammatory processes in autoimmune diseases. Clearly a 
deeper characterization of the molecular pathways regulated by 
CD28 and PIP5Kα is required to open up new avenues to target 
PIP5Kα.
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